SynAct Pharma has secured a strategic financing facility of up to SEK 100 million and resolved on an initial drawdown of SEK 50 million in the form of convertible loans. The capital is intended to support the company’s ongoing partnering discussions and to fund preparations for Phase III development. BioStock reached out to CEO Jeppe Øvlesen for a comment.
Read the full interview at biostock.se:
SynAct comments on the SEK 100 million facility
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/
Follow BioStock
Read the latest news, keep track of upcoming events, explore BioStock Analytics' in-depth analyses and watch the latest videos! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!
About BioStock
BioStock is the Nordic region's leading information channel for life science. Focusing on biotech, medtech, diagnostics and pharmaceutical development, we provide daily news updates, in-depth analyses via BioStock Analytics, exclusive interviews and innovation-driving networking events – all to keep you up to date on developments in the sector.
BioStock – Connecting Innovation & Capital.